FDA Grants Fast Track Designation for BioCryst ’s ALK-2 Inhibitor, BCX9250

RESEARCH TRIANGLE PARK, N.C., June 08, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BCX9250 for the prevention of...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials